properdin
complement
amlitelimab
zanolimumab
intetumumab
seroimmunity
antiserum
immunome
active immunity
antiantibody
MYD88
alloantibody
immunoexpression
glembatumumab
immunoprotein
cytokine
presentation
gamma globulin
human gamma globulin
namilumab
antihuman
elotuzumab
tucotuzumab
sonepcizumab
soravtansine
antigenomic
ipilimumab
immunosubunit
bivatuzumab
monospecific
carlumab
immunodeposition
affinity
hematoimmune
agonistic monoclonal antibody
immunodeposit
secukinumab
ocrelizumab
bursopentine
immunoexpress
talizumab
sifalimumab
-lim-
immunocompetence
muromonab
pathoantigen
hyperimmunoglobulin
intrabody
vobarilizumab
immunoarchitecture
allotype
immunogen
immunoprecipitant
complementology
affibody
immunoadaptor
mavrilimumab
immunoproteomics
-ab
vepalimomab
ruplizumab
immunoprecipitate
immune privilege
immunology
gimsilumab
immunopeptide
adjuvant
auto-immune
olendalizumab
-zumab
envoplakin
tisotumab
immunoresponsive
immunoserum
immunosystem
immunoglobulin D
IgD
immunocytic
antisubstance
immunoantigen
immunoreactant
recognition
immunohistopathology
paratope
sirukumab
reagin
histocompatibility antigen
faralimomab
microantibody
antigenic
onartuzumab
seroconversion
immunocompetent
immunoblotting
otilimab
bispecific
immunoglobin